FI75153C - Foerfarande foer framstaellning av nya farmakologiskt aktiva (4r*,5as*)-4,5,5a,6-tetrahydro-dibens/cd,f/indolderivat. - Google Patents
Foerfarande foer framstaellning av nya farmakologiskt aktiva (4r*,5as*)-4,5,5a,6-tetrahydro-dibens/cd,f/indolderivat. Download PDFInfo
- Publication number
- FI75153C FI75153C FI811922A FI811922A FI75153C FI 75153 C FI75153 C FI 75153C FI 811922 A FI811922 A FI 811922A FI 811922 A FI811922 A FI 811922A FI 75153 C FI75153 C FI 75153C
- Authority
- FI
- Finland
- Prior art keywords
- formula
- compound
- tetrahydro
- ethyl
- group
- Prior art date
Links
- 230000000694 effects Effects 0.000 title description 6
- 230000000144 pharmacologic effect Effects 0.000 title 2
- 238000009313 farming Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 71
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 125000001033 ether group Chemical group 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 239000012458 free base Substances 0.000 claims description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 230000010933 acylation Effects 0.000 claims description 3
- 238000005917 acylation reaction Methods 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
- 239000000243 solution Substances 0.000 description 23
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 10
- 239000007858 starting material Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 9
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000003291 dopaminomimetic effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- -1 4-n-propyldibenz [cd, f] indole hydrobromide Chemical compound 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 102000003946 Prolactin Human genes 0.000 description 4
- 108010057464 Prolactin Proteins 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- RJTZUHVCZIGJMB-UHFFFAOYSA-N hydron;1h-indole;chloride Chemical compound Cl.C1=CC=C2NC=CC2=C1 RJTZUHVCZIGJMB-UHFFFAOYSA-N 0.000 description 4
- 229940097325 prolactin Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 3
- DRHKAJZMZVLERV-UHFFFAOYSA-N n-(3,4-dimethoxyphenanthren-9-yl)acetamide Chemical compound C1=CC=C2C3=C(OC)C(OC)=CC=C3C=C(NC(C)=O)C2=C1 DRHKAJZMZVLERV-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000008024 pharmaceutical diluent Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- PKZXKYOUTNKIMK-UHFFFAOYSA-N 3,4-dimethoxyphenanthren-9-amine Chemical compound C1=CC=C2C3=C(OC)C(OC)=CC=C3C=C(N)C2=C1 PKZXKYOUTNKIMK-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000009132 Catalepsy Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 102000004659 Presynaptic Receptors Human genes 0.000 description 2
- 108010003717 Presynaptic Receptors Proteins 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960002523 mercuric chloride Drugs 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- NYFMUOLWACUBDV-UHFFFAOYSA-N n-ethyl-3,4-dimethoxyphenanthren-9-amine Chemical compound C1=CC=C2C(NCC)=CC3=CC=C(OC)C(OC)=C3C2=C1 NYFMUOLWACUBDV-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- NGEVMZJCGSABFB-LSDHHAIUSA-N (9R,11S)-10,11-diethyl-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),2(7),3,5,12,14-hexaene-3,4-diol Chemical compound C(C)[C@@H]1N([C@@H]2CC3=C(C4=C2C1=CC=C4)C(=C(C=C3)O)O)CC NGEVMZJCGSABFB-LSDHHAIUSA-N 0.000 description 1
- MFPAAMAFZKTMDJ-DLBZAZTESA-N (9R,11S)-10,11-dipropyl-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),2(7),3,5,12,14-hexaene-3,4-diol Chemical compound C1C2=CC=C(O)C(O)=C2C2=CC=CC3=C2[C@@H]1N(CCC)[C@H]3CCC MFPAAMAFZKTMDJ-DLBZAZTESA-N 0.000 description 1
- BHEHLHMIZRTZJI-ZWKOTPCHSA-N (9R,11S)-10-ethyl-3,4-dimethoxy-11-propyl-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),2(7),3,5,12,14-hexaene Chemical compound C(C)N1[C@H](C=2C3=C(C4=C(C[C@@H]13)C=CC(=C4OC)OC)C=CC2)CCC BHEHLHMIZRTZJI-ZWKOTPCHSA-N 0.000 description 1
- KMDJVZQFYPQGNF-UHFFFAOYSA-N 10-ethyl-3,4-dimethoxy-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1,3,5,7,9(16),12,14-heptaen-11-one Chemical compound O=C1N(CC)C2=CC3=CC=C(OC)C(OC)=C3C3=C2C1=CC=C3 KMDJVZQFYPQGNF-UHFFFAOYSA-N 0.000 description 1
- UARUVPSHLDRXIZ-UHFFFAOYSA-N 10-ethyl-3,4-dimethoxy-11-propyl-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1,3,5,7,9(16),12,14-heptaen-11-ol Chemical compound C(C)N1C(C=2C=3C(=C4C(=CC13)C=CC(=C4OC)OC)C=CC2)(CCC)O UARUVPSHLDRXIZ-UHFFFAOYSA-N 0.000 description 1
- BVKHTQPZFFSBTJ-UHFFFAOYSA-N 15-propyl-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1(15),2,4,6,8,10,12(16),13-octaene Chemical compound C1=NC2=CC3=CC=CC=C3C3=C2C1=CC=C3CCC BVKHTQPZFFSBTJ-UHFFFAOYSA-N 0.000 description 1
- UUAIGYUJQOIJQK-UHFFFAOYSA-N 1h-phenanthro[9,10-b]pyrrole Chemical compound C12=CC=CC=C2C2=CC=CC=C2C2=C1NC=C2 UUAIGYUJQOIJQK-UHFFFAOYSA-N 0.000 description 1
- OFKWWALNMPEOSZ-UHFFFAOYSA-N 3-(hydrazinylmethyl)phenol Chemical compound NNCC1=CC=CC(O)=C1 OFKWWALNMPEOSZ-UHFFFAOYSA-N 0.000 description 1
- KWVAVJZJXVTILI-UHFFFAOYSA-N 8-bromo-n-ethyl-3,4-dimethoxyphenanthren-9-amine Chemical compound C1=CC(Br)=C2C(NCC)=CC3=CC=C(OC)C(OC)=C3C2=C1 KWVAVJZJXVTILI-UHFFFAOYSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UEIXJNMPGFVFIC-OXMSDDLCSA-N C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C)N1[C@H](C=2C3=C(C4=C(C[C@@H]13)C=CC(=C4OC(C4=CC=CC=C4)=O)OC(C4=CC=CC=C4)=O)C=CC2)CCC Chemical compound C(=O)(O)[C@H](O)[C@@H](O)C(=O)O.C(C)N1[C@H](C=2C3=C(C4=C(C[C@@H]13)C=CC(=C4OC(C4=CC=CC=C4)=O)OC(C4=CC=CC=C4)=O)C=CC2)CCC UEIXJNMPGFVFIC-OXMSDDLCSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- NUDHZXAKQVKXFS-CMXBXVFLSA-N Cl.C(C)(=O)OC=1C=CC2=C(C3=C4C([C@@H](N([C@@H]4C2)CC)CCC)=CC=C3)C1OC(C)=O Chemical compound Cl.C(C)(=O)OC=1C=CC2=C(C3=C4C([C@@H](N([C@@H]4C2)CC)CCC)=CC=C3)C1OC(C)=O NUDHZXAKQVKXFS-CMXBXVFLSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 239000001358 L(+)-tartaric acid Substances 0.000 description 1
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N L-(+)-Tartaric acid Natural products OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- QSPPMGNXYVCZBS-WUFINQPMSA-N [(9R,11S)-3-benzoyloxy-10-ethyl-11-propyl-10-azatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),2(7),3,5,12,14-hexaen-4-yl] benzoate Chemical compound C(C)N1[C@H](C=2C3=C(C4=C(C[C@@H]13)C=CC(=C4OC(C4=CC=CC=C4)=O)OC(C4=CC=CC=C4)=O)C=CC2)CCC QSPPMGNXYVCZBS-WUFINQPMSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000000593 indol-1-yl group Chemical group [H]C1=C([H])C([H])=C2N([*])C([H])=C([H])C2=C1[H] 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- BQPIGGFYSBELGY-UHFFFAOYSA-N mercury(2+) Chemical compound [Hg+2] BQPIGGFYSBELGY-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- NGHSAAXKBIWRBD-UHFFFAOYSA-N n-(3-bromo-3,4-dimethoxy-2h-phenanthren-9-yl)-n-ethylbutanamide Chemical compound C1=CC=C2C(N(CC)C(=O)CCC)=CC3=CCC(Br)(OC)C(OC)=C3C2=C1 NGHSAAXKBIWRBD-UHFFFAOYSA-N 0.000 description 1
- FTKRHYDMKGPKQG-UHFFFAOYSA-N n-(8-bromo-3,4-dimethoxyphenanthren-9-yl)-n-ethylbutanamide Chemical compound C1=CC(Br)=C2C(N(CC)C(=O)CCC)=CC3=CC=C(OC)C(OC)=C3C2=C1 FTKRHYDMKGPKQG-UHFFFAOYSA-N 0.000 description 1
- MJFVSNHXRYJOLC-UHFFFAOYSA-N n-amino-n-benzylhydroxylamine Chemical compound NN(O)CC1=CC=CC=C1 MJFVSNHXRYJOLC-UHFFFAOYSA-N 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002987 phenanthrenes Chemical class 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 230000028838 turning behavior Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH497280 | 1980-06-27 | ||
| CH497280 | 1980-06-27 | ||
| GB8037586 | 1980-11-24 | ||
| GB8037586 | 1980-11-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI811922L FI811922L (fi) | 1981-12-28 |
| FI75153B FI75153B (fi) | 1988-01-29 |
| FI75153C true FI75153C (fi) | 1988-05-09 |
Family
ID=25696642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI811922A FI75153C (fi) | 1980-06-27 | 1981-06-18 | Foerfarande foer framstaellning av nya farmakologiskt aktiva (4r*,5as*)-4,5,5a,6-tetrahydro-dibens/cd,f/indolderivat. |
Country Status (22)
| Country | Link |
|---|---|
| AT (1) | AT380875B (es) |
| AU (1) | AU546599B2 (es) |
| CA (1) | CA1155447A (es) |
| CY (1) | CY1399A (es) |
| DE (1) | DE3124086A1 (es) |
| DK (1) | DK285481A (es) |
| ES (3) | ES503432A0 (es) |
| FI (1) | FI75153C (es) |
| FR (2) | FR2485530A1 (es) |
| GB (1) | GB2136418B (es) |
| IE (1) | IE51341B1 (es) |
| IL (1) | IL63174A (es) |
| IT (1) | IT8148776A0 (es) |
| KE (1) | KE3749A (es) |
| NL (1) | NL8103041A (es) |
| NZ (1) | NZ197529A (es) |
| PH (1) | PH22773A (es) |
| PT (1) | PT73258B (es) |
| SE (1) | SE449222B (es) |
| SG (1) | SG62087G (es) |
| WO (1) | WO1982000143A1 (es) |
| YU (1) | YU159481A (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH647507A5 (de) * | 1982-04-13 | 1985-01-31 | Sandoz Ag | Heterozyklische verbindungen, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, welche diese verbindungen enthalten. |
| AT381090B (de) * | 1983-04-12 | 1986-08-25 | Sandoz Ag | Herstellung von neuen (4r*,5as*)2,4,5-trialkylch8204132231/8 |
| US4795759A (en) * | 1985-07-27 | 1989-01-03 | Sandoz Ltd. | Use of dibenz(CD,F)indoles |
| US5220536A (en) * | 1989-09-01 | 1993-06-15 | Quantronix, Inc. | Measuring method and apparatus |
| US5422861A (en) * | 1989-09-01 | 1995-06-06 | Quantronix, Inc. | Measuring method and apparatus |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK249379A (da) * | 1978-06-23 | 1980-01-22 | Sandoz Ag | Fremgangsmaade til fremstilling af phenanthrenderivater |
| BE877169A (fr) * | 1978-06-23 | 1979-12-21 | Sandoz Sa | Nouveaux derives du phenantrene, leur preparation et leur application comme medicaments |
-
1981
- 1981-06-18 FI FI811922A patent/FI75153C/fi not_active IP Right Cessation
- 1981-06-19 DE DE19813124086 patent/DE3124086A1/de not_active Withdrawn
- 1981-06-22 FR FR8112367A patent/FR2485530A1/fr active Granted
- 1981-06-22 AU AU72028/81A patent/AU546599B2/en not_active Ceased
- 1981-06-24 NL NL8103041A patent/NL8103041A/nl not_active Application Discontinuation
- 1981-06-24 CY CY139981A patent/CY1399A/en unknown
- 1981-06-24 WO PCT/CH1981/000069 patent/WO1982000143A1/de not_active Ceased
- 1981-06-25 SE SE8103983A patent/SE449222B/sv not_active IP Right Cessation
- 1981-06-25 IE IE1421/81A patent/IE51341B1/en unknown
- 1981-06-25 CA CA000380614A patent/CA1155447A/en not_active Expired
- 1981-06-25 IL IL63174A patent/IL63174A/xx unknown
- 1981-06-25 PT PT73258A patent/PT73258B/pt unknown
- 1981-06-25 YU YU01594/81A patent/YU159481A/xx unknown
- 1981-06-25 NZ NZ197529A patent/NZ197529A/en unknown
- 1981-06-26 ES ES503432A patent/ES503432A0/es active Granted
- 1981-06-26 DK DK285481A patent/DK285481A/da not_active Application Discontinuation
- 1981-06-26 AT AT0284481A patent/AT380875B/de not_active IP Right Cessation
- 1981-06-26 PH PH25823A patent/PH22773A/en unknown
- 1981-06-26 IT IT8148776A patent/IT8148776A0/it unknown
-
1982
- 1982-09-02 FR FR8215401A patent/FR2510996A1/fr not_active Withdrawn
- 1982-09-08 ES ES515567A patent/ES515567A0/es active Granted
- 1982-09-08 ES ES515568A patent/ES8400089A1/es not_active Expired
-
1983
- 1983-09-27 GB GB08325760A patent/GB2136418B/en not_active Expired
-
1987
- 1987-07-31 SG SG620/87A patent/SG62087G/en unknown
- 1987-08-14 KE KE3749A patent/KE3749A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0995743B1 (fr) | Dérivés de dihydro- et tétrahydroquinoléine en tant qu'antioxydant médical | |
| EP0010029B1 (fr) | Ellipticines substituées en position 1 par une chaîne polyaminée, leur synthèse et médicaments les contenant | |
| PT701819E (pt) | Novas composicoes contendo sertralina e um agonista ou antagonista de receptor de 5-ht1d | |
| US5164404A (en) | Hydrazone derivatives and their use | |
| HU190703B (en) | Process for preparing new 1,2,3,4,4a,5,10,10a-octahydro-benzo/g/-quinoline derivatives | |
| FR2574793A1 (fr) | Composes derives d'indole, compositions pharmaceutiques les contenant et procede pour leur preparation | |
| US4238486A (en) | Indolobenzoxazines | |
| FI75153C (fi) | Foerfarande foer framstaellning av nya farmakologiskt aktiva (4r*,5as*)-4,5,5a,6-tetrahydro-dibens/cd,f/indolderivat. | |
| US4851429A (en) | Pharmaceutically useful tricyclic amines derived from 2,3,5,6,7,8-hexahydronaphtho(2,3-B)furan and from 2,3,6,7,8,9-hexahydro-5H-benzocyclohepta(2,3-B)furan | |
| EP0402232A1 (fr) | Dérivés de pyridobenzoindole, leur préparation et les compositions qui les contiennent | |
| HUP9904054A2 (hu) | COX-2 piranoindol és karbazol inhibitorai | |
| FR2508457A1 (fr) | Pyrrolo(2,1-b)quinazolines et pyrido(2,1-b)quinazolines substituees, leur preparation et leurs utilisations therapeutiques | |
| GB2078225A (en) | 4,5,5a,6-tetrahydro-dibenz[cd,f]indoles | |
| WO1996020927A1 (en) | DIBENZ[cd,f]INDOLE DERIVATIVES | |
| JPH09508917A (ja) | フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用 | |
| FI78072B (fi) | Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara (4r*,5as*)-2-alkyl-9,10-dihydro-4,5,5a,6- tetrahydro-dibens/cd,f/indoler. | |
| FR2476649A1 (fr) | Nouveaux derives du cycloheptindole, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant | |
| US4150136A (en) | Benz[g]isoquinolines and use thereof | |
| NZ204616A (en) | 4,5-dialkyl-9,10-dialkoxy-4,5,5a,6-tetrahydrodibenz(cd,f)indoles | |
| CA1162927A (en) | Heterocyclic compounds, their preparation and pharmaceutical compositions containing them | |
| CS268187B2 (en) | Method of new tetrahydrobenzothiazolo-quinolines production | |
| HUP0103518A2 (hu) | Új 2,3,3a,4,9,9a-hexahidro-8-hidroxi-1H-benz[f]indol-származékok, eljárás előállításukra és alkalmazásuk gyógyszerkészítmények előállítására | |
| CH660187A5 (en) | Dibenz[cd,f]indole derivatives, their preparation and the pharmaceutical compositions containing them | |
| FR2795729A1 (fr) | Nouveaux derives de la benzo[f]naphtyridine, leur preparation et les compositions les contenant | |
| CH649288A5 (en) | Tetrahydrobenzindoles, process for their preparation and pharmaceutical compositions which contain these compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: SANDOZ AG |